Mr. Larsen co-founded Vesselon in 2012 and brings over thirty years
of executive management, marketing, sales, clinical innovation and engineering/project management
in the healthcare industry. Mr. Larsen was a senior executive with FUJIFILM Medical Systems,
where he was largely responsible for building the company’s first healthcare software division
from the ground up. Mr. Larsen recruited the original senior architects and was instrumental
in the development, marketing, commercial release and field support of Fuji's Synapse® Picture
Archive and Communication System (PACS).
In a move to Silicon Valley in 1988, Mr. Larsen served in several senior roles at Acuson Corporation culminating as Vice President of New Market Development. Acuson was one of the leading ultrasound technology companies that was later acquired by Siemens. Early in his career he specialized in Sales and Marketing Management of Ultrasound and Nuclear Medicine for Picker International. Mr. Larsen holds a B.S. in Molecular Biophysics and Biochemistry from Yale University.
Mr. Li is the founder of Vesselon and is a serial healthcare entrepreneur. He brings more than thirty years of experience in finance, business development, strategy, patents and regulatory submissions. Mr. Li continues to direct the company's strategy and has secured multiple assets and licenses to key patents for the combination of therapeutics utilizing the company's platform technology. Prior to founding Vesselon, Mr. Li worked in both healthcare private equity and investment banking. Mr. Li co-founded an orthopedic implant company, Li Medical Technologies, which developed and sold sports medicine and spinal implants. Li Medical was venture capital funded and was acquired by Conmed Corporation. Mr. Li has five issued patents and additional pending patents
Neil Edwards joined Vesselon as CFO in December 2019 bringing 30 years of business execution strategy and fund-raising experience to the team. Edwards served in C-suite roles in Interos, VeriSign, infoGroup, and dotMobi over his career. As CEO of dotMobi, he secured investments from Google, Vodaphone, Visa, and Samsung. As CRO at Interos.ai, he led the Kleiner Perkins funding and acquisition of Trensant. Edwards is a regular contributor with Forbes and sits on several boards. He holds a B.A. in Mathematics & Computer Science from The Citadel, and completed graduate work at Duke University.
Llew Keltner, M.D., Ph.D., has a 40-year career in biopharma drug and business development. He is Chief Executive Officer of EPISTAT, an international healthcare technology transfer, corporate risk management and healthcare strategy company that he founded in 1972. Dr. Keltner was the Chief Executive Officer of AgonOx, a biotech company developing OX40 agonists for use in cancer therapy, from 2011 to 2013. He was the President of Novici Biotech, a privately-held gene and protein optimization firm in 2010 and 2011. Dr. Keltner was Chief Executive Officer and President of Light Sciences Oncology, a privately-held biotechnology company developing a late stage, light-activated therapy for hepatocellular cancer and other solid tumors from 2001 to 2010. From 1997 to 2004, Dr. Keltner was Chief Executive Officer of Metastat, a development-stage biotech company focused on cancer metastasis. Dr. Keltner holds positions on the boards of Curetech, Infostat, BioQ Pharma, Oregon Life Sciences, Surgeon Training International, OncoSCAR, and Goodwell Technologies. He is a previous Director of Raptor Pharmaceuticals, where he served as Chairman (NASDAQ:RPTP), Light Sciences Corporation, Immunovaccine (TSX.V:IMV),Vital Choice, Thesis Technologies, Oread Companies, and MannKind Corporation (NASDAQ:MNKD). He has also been a scientific advisory board member at Heat Biologics, Pelican Therapeutics, Lifetime Corporation, ASB Meditest, Oread Laboratories, Hall-Kimbrell, and aai Pharma. Dr. Keltner is an Associate Professor at Case Western Reserve School of Medicine, and a Guest Lecturer and Director in the Bioethics Program at Columbia University School of Medicine. He is currently a member of the American Society of Clinical Oncology, American Association of Cancer Research, American Medical Association, International Association of Tumor Marker Oncology, American Association of Clinical Chemistry, and Drug Information Association. Dr. Keltner received an M.S. in Epidemiology and Biostatistics, a Ph.D. in Biomedical Informatics and an M.D. from Case Western Reserve University in Cleveland, Ohio. Dr. Keltner has also authored many research publications.
Adam Levy, PhD, MBA, is currently EVP, Investor Relations and Corporate Communications at Ziopharm Oncology. Prior to this role, Dr. Levy was Executive Director and Head, Corporate Strategy and Investor Relations for Gilead Sciences. Previously, Dr. Levy was VP, Corporate Strategy for Alexion and Executive Director, Corporate Strategy for Bristol-Myers Squibb. He also has held prior leadership positions with Novartis and served as a consultant at McKinsey & Company. Adam holds a B.S. in Genetics and a Ph.D. in Molecular Biology, both from the University of Illinois and an MBA in Finance and Strategy from Northwestern University Kellogg School of Management.
Steve Mahoney has over 20 years of biotechnology and health care industry experience. He is currently the Chief Financial and Operating Officer of Magenta Therapeutics, Inc. focused on improving stem cell transplantation across a variety of diseases areas, including hematology oncology. He was previously President and Chief Operating Officer of Kiniksa Pharmaceuticals which acquired/in-licensed multiple product candidates at different stages of clinical development for further advancement. Prior to this role, Steve was the Chief Commercial Officer of Synageva Biopharma prior to its acquisition by Alexion Pharmaceuticals and previously held various roles over a 10 year tenure at Genzyme Corporation. Steve holds an MBA and JD from Boston College and a BA from Colorado College.
Chairman of Spencer Trask & Co. Helped start ventures that created and commercialized landmark products in cancer genomics, immunotherapy and cellular therapy. Myriad Genetics discovered the BRCA1 breast cancer gene. His Immune Response Corporation venture with Jonas Salk developed the first FDA-approved cancer vaccine. Osiris Therapeutics created the world’s first approved universal stem cell drug. As a founding shareholder in Bob Langer’s first company, Enzytech (Alkermes), Kimberlin observed how Langer’s lipid research came to protect the mRNA in Moderna’s COVID-19 vaccine.
Jay Galeota was the President and Chief Executive Officer of Inheris BioPharma, Inc. until May, 2020. Prior to that, Jay was President and Chief Operating Officer of G&W Laboratories, Inc. and Chief Strategy & Business Development Officer and President, Emerging Business at Merck & Co., Inc. He is a 31-year industry veteran and spent 28 years at Merck, where he served in many diverse positions across commercial operations, business development, strategy, and innovation, both globally and in the U.S. Jay is known for his passion for innovation and development of break-through products and business opportunities. Jay holds a Bachelor of Science degree in biology from Villanova University and is a graduate of Harvard Business School’s Advanced Management Program. He served as an Independent Director at Melinta Therapeutics, Inc. (MLNT) and Assertio Therapeutics, Inc. (ASRT), and is on the boards of Hackensack Meridian Health System, Harvard Business School’s Healthcare Alumni Association, the New Jersey Symphony Orchestra, and the Metuchen Edison Woodbridge YMCA. Jay is also a member of Villanova University’s Deans Advisory Council. In addition, Jay currently serves as the Honorary Commander of the United States Air Force 113th Wing, DCANG, Joint Base Andrews and has been a guest lecturer at the Wharton School of the University of Pennsylvania. Jay is also the co-author of several publications in Harvard Business Review and Chief Executive. Jay currently resides in New Jersey with his wife and three children. In addition to business, his interests include sailing, skiing, flying, automobiles and music.
President and CEO
Founder, Executive VP, and Strategy
Chief Financial Officer
Clinical Research, Thoracic Oncology
UNC, Lineberger Comprehensive Cancer Center
Chief, Division Hematology Oncology
Weill Cornell Medicine
Laboratory of Cancer Immunotherapy
Providence Portland Medical Center
Chief Technical Advisor
UC San Diego School of Medicine